Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences ADME and Predictive Toxicology

Robert Guttendorf's Biography

Robert Guttendorf, Senior Consultant, DMPK, Aclairo Pharmaceutical Development Group

Robert J. Guttendorf, R.Ph, Ph.D. is a Senior Consultant, DMPK, at Aclairo Pharmaceutical Development Group, Inc. in Vienna, VA. Dr. Guttendorf provides scientific, regulatory, strategic planning, and due diligence advice and support for drug discovery and development. He has held leadership positions in small biotech and large pharmaceutical companies, including Director of Discovery and Preclinical Development at Pfizer Global R&D and Parke-Davis Pharmaceutical Research, Scientific Strategy Advisor at Pfizer, Vice President of Pharmacology and Biopharmaceutics at Advancis (Middlebrook) Pharmaceutical Co., and Vice President of Pharmacology and Experimental Therapeutics at Sequoia Pharmaceuticals. He has directed ADME/PK support for discovery through NDA across a variety of therapeutic areas, overseeing numerous nonclinical pharm-tox and clinical pharmacology programs, and a host of regulatory submissions. At Parke-Davis/Pfizer, he helped pioneer the implementation of higher throughput ADME/PK screening approaches in drug discovery and was instrumental in defining best practices for DMPK in drug discovery and development. In addition, he led Pfizer’s Global PDM organization in evaluating and implementing new strategies to enhance the quality and R&D survival of exploratory development candidates. He has presented and published numerous papers on various topics in ADME/PK, including the strategic use of ADME data to improve drug discovery and development. He received a B.S. in Pharmacy from West Virginia University and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky.

Robert Guttendorf Image

What is the Role of GLPs in ADME?

Friday, 12 April 2013 at 14:15

Add to Calendar ▼2013-04-12 14:15:002013-04-12 15:15:00Europe/LondonWhat is the Role of GLPs in ADME?ADME and Predictive Toxicology in Barcelona, SpainBarcelona,

Pivotal nonclinical safety studies are required to adhere to Good Laboratory Practice (GLP) guidelines.  Recent trends suggest that nonclinical ADME studies are increasingly being conducted by GLP.  Is this now a requirement? Will it be required in the future?  

Add to Calendar ▼2013-04-11 00:00:002013-04-12 00:00:00Europe/LondonADME and Predictive ToxicologyADME and Predictive Toxicology in Barcelona, SpainBarcelona,